<--- Back to Details
First PageDocument Content
Organic chemistry / Organofluorides / Treatment of bipolar disorder / Mental health / Mood disorders / Antidepressant / Paroxetine / Sertraline / Fluoxetine / Psychiatry / Chemistry / Selective serotonin reuptake inhibitors
Date: 2005-09-19 23:41:13
Organic chemistry
Organofluorides
Treatment of bipolar disorder
Mental health
Mood disorders
Antidepressant
Paroxetine
Sertraline
Fluoxetine
Psychiatry
Chemistry
Selective serotonin reuptake inhibitors

Graduate Student Journal of Psychology 2005, Vol. 7 Copyright 2005 by the Department of Counseling & Clinical Psychology Teachers College, Columbia University ISSN[removed]

Add to Reading List

Source URL: www.tc.columbia.edu

Download Document from Source Website

File Size: 146,35 KB

Share Document on Facebook

Similar Documents

Menopause Publishes Pivotal Trial Results for Brisdelle™ (Paroxetine) Capsules, an FDA-Approved Non-Hormonal Therapy for Vasomotor Symptoms Associated with Menopause Miami, FL and New York, NY, September 18, 2013 – N

Menopause Publishes Pivotal Trial Results for Brisdelle™ (Paroxetine) Capsules, an FDA-Approved Non-Hormonal Therapy for Vasomotor Symptoms Associated with Menopause Miami, FL and New York, NY, September 18, 2013 – N

DocID: 1vh4h - View Document

Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopa

Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopa

DocID: 1uLvr - View Document

Noven Pharmaceuticals Announces Issuance of New U.S. Patent, an Important Addition to its Intellectual Property Portfolio for Brisdelle® (Paroxetine) Capsules, 7.5 mg MIAMI and NEW YORK, March 25, 2014 – Noven Pharmac

Noven Pharmaceuticals Announces Issuance of New U.S. Patent, an Important Addition to its Intellectual Property Portfolio for Brisdelle® (Paroxetine) Capsules, 7.5 mg MIAMI and NEW YORK, March 25, 2014 – Noven Pharmac

DocID: 1tRNZ - View Document

Do not take extra medicine to treat tadalafil super active attention deficit hyperactivity disorder . an antidepressant--citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline. Answers from Donald Hens

Do not take extra medicine to treat tadalafil super active attention deficit hyperactivity disorder . an antidepressant--citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline. Answers from Donald Hens

DocID: 1sM49 - View Document

formulation of paroxetine. paroxetine canadian pharmacy methadone and paroxetine interaction, paroxetine long term side effects manufactuer of paroxetine tablets paroxetine withdrawal paroxetine hcl 25 mg, generic paroxe

formulation of paroxetine. paroxetine canadian pharmacy methadone and paroxetine interaction, paroxetine long term side effects manufactuer of paroxetine tablets paroxetine withdrawal paroxetine hcl 25 mg, generic paroxe

DocID: 1rNxr - View Document